HC Wainwright Expects Weaker Earnings for Xeris Biopharma

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) – Analysts at HC Wainwright cut their FY2029 earnings per share estimates for shares of Xeris Biopharma in a research note issued on Friday, November 6th. HC Wainwright analyst B. Folkes now anticipates that the company will earn $0.63 per share for the year, down from their previous estimate of $0.65. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is $0.07 per share.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a positive return on equity of 429.43% and a negative net margin of 1.76%. The company had revenue of $107.23 million during the quarter, compared to analysts’ expectations of $101.68 million.

A number of other equities analysts also recently issued reports on the company. Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday. Piper Sandler reissued a “neutral” rating and set a $12.00 price objective (up from $8.00) on shares of Xeris Biopharma in a research report on Friday. Barclays boosted their target price on shares of Xeris Biopharma from $12.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, October 6th. Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Leerink Partners upped their target price on shares of Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a research report on Thursday, September 10th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Xeris Biopharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.20.

View Our Latest Stock Analysis on Xeris Biopharma

Xeris Biopharma Price Performance

Shares of XERS stock opened at $15.20 on Monday. The stock has a market cap of $2.78 billion, a price-to-earnings ratio of -303.94 and a beta of 0.61. The business’s fifty day moving average is $9.62 and its 200 day moving average is $7.62. Xeris Biopharma has a twelve month low of $5.25 and a twelve month high of $15.21. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00.

Institutional Trading of Xeris Biopharma

Several institutional investors have recently bought and sold shares of the company. GK Wealth Management LLC bought a new stake in Xeris Biopharma during the 3rd quarter valued at about $32,000. Allworth Financial LP purchased a new position in Xeris Biopharma in the second quarter worth about $34,000. KBC Group NV purchased a new position in Xeris Biopharma in the first quarter worth about $27,000. William Mack & Associates Inc. bought a new position in shares of Xeris Biopharma in the third quarter worth approximately $53,000. Finally, Sterling Capital Management LLC lifted its stake in shares of Xeris Biopharma by 848.0% in the third quarter. Sterling Capital Management LLC now owns 5,707 shares of the company’s stock worth $55,000 after buying an additional 5,105 shares in the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Xeris Biopharma

In other news, insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $10.23, for a total value of $51,150.00. Following the completion of the transaction, the insider owned 1,346,053 shares of the company’s stock, valued at $13,770,122.19. The trade was a 0.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $12.49, for a total value of $312,250.00. Following the completion of the transaction, the insider directly owned 1,559,208 shares of the company’s stock, valued at approximately $19,474,507.92. This represents a 1.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 173,332 shares of company stock valued at $1,721,471. Insiders own 4.35% of the company’s stock.

Trending Headlines about Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

  • Positive Sentiment: Q3 results beat expectations: Xeris reported earnings of $0.06 per share versus a $0.03 consensus estimate, while revenue of $107.23 million exceeded forecasts of $101.68 million. The results provide evidence of stronger-than-expected performance. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
  • Positive Sentiment: Analysts raised targets: Oppenheimer reaffirmed its “outperform” rating and lifted its target to $21 from $18. HC Wainwright kept a “buy” rating and raised its target to $18 from $10. These revisions suggest greater optimism about Xeris’s prospects. Oppenheimer ratings HC Wainwright ratings
  • Positive Sentiment: Recorlev sales outlook: CEO John Shannon reportedly sees the drug approaching $1 billion in annual sales three to four years earlier than previously expected, a potentially meaningful growth driver. CEO comments on Recorlev sales outlook
  • Neutral Sentiment: Insider Kevin McCulloch sold 25,000 shares under a pre-arranged Rule 10b5-1 plan, a modest reduction; he retained more than 1.55 million shares. SEC Form 4 filing
  • Negative Sentiment: Cautious analyst view: Piper Sandler reaffirmed “neutral” despite raising its target to $12 from $8. That target remains below the share price cited in the report, signaling valuation concerns. Piper Sandler ratings

About Xeris Biopharma

(Get Free Report)

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.

Recommended Stories

Earnings History and Estimates for Xeris Biopharma (NASDAQ:XERS)

Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.